PM1003 / BioNTech - LARVOL DELTA

A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors (ESMO 2023) - "Conclusions PM1003 was well-tolerated at doses up to 10 mg/kg and preliminary antitumor efficacy was observed in a patient with prior anti-PD-1 treatment. Expansion cohorts to evaluate efficacy and further safety in PD-L1-positive pts are ongoing."

Clinical • IO biomarker • Metastases • P1/2 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors. (ASCO 2023) - "PM1003 was well-tolerated up to 6 mg/kg and has shown preliminary anti-tumor activity in a patient who was previously treated with multiple drug modalities including anti-PD-1. The dose-escalation at 10 mg/kg and dose expansion are ongoing. Clinical trial information: ChiCTR2100052887."

Clinical • Metastases • P1 data • Anemia • Fatigue • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Oncology • Solid Tumor

Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1/2 | N=285 | Recruiting | Sponsor: Biotheus Inc.

Metastases • New P1/2 trial • Oncology • Solid Tumor

Discovery of a safer 4-1BB agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging (SITC 2021) - "This was reflected in our results. Thus, PM1003 is a potential next generation therapeutic antibody in the IO space that combines and synergizes two independent signaling pathways to control tumor growth."

Oncology • IFNG • IL2